Cancer vaccines inducing antibody production: More pros than cons

Erika Jensen-Jarolim*, Josef Singer

*Korrespondierende:r Autor:in für diese Arbeit

Publikation: Beitrag in Fachzeitschrift (peer-reviewed)Übersichtsartikel

15 Zitate (Scopus)

Abstract

To date, passive immunotherapy with monoclonal antibodies is a well-established option in clinical oncology. By contrast, anticancer Vaccines are less advanced, with the exception of successfully applied prophylactic vaccines against oncogenic virus infections. The creation of therapeutic vaccines is still a great challenge mostly due to the self-nature of tumor antigens. Therapeutic vaccines may be based on patient-specific material including pulsed effector cells, or tumor-associated antigens and derivatives thereof, such as peptides, mimotopes and nucleic acids. The latter represents a more universal approach, which would set an ideal economic framework resulting in broad patient access. In this article we focus on cancer vaccines for antibody production, in particular mimotope vaccines. The collected evidence suggests that they will open up new treatment options in minimal residual disease and early stage disease.

OriginalspracheEnglisch
Seiten (von - bis)1281-1289
Seitenumfang9
FachzeitschriftExpert Review of Vaccines
Jahrgang10
Ausgabenummer9
DOIs
PublikationsstatusVeröffentlicht - Sept. 2011
Extern publiziertJa

ASJC Scopus Sachgebiete

  • Immunologie
  • Molekularmedizin
  • Pharmakologie
  • Wirkstoffforschung

Fingerprint

Untersuchen Sie die Forschungsthemen von „Cancer vaccines inducing antibody production: More pros than cons“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren